CA2650999A1 - Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases - Google Patents
Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases Download PDFInfo
- Publication number
- CA2650999A1 CA2650999A1 CA002650999A CA2650999A CA2650999A1 CA 2650999 A1 CA2650999 A1 CA 2650999A1 CA 002650999 A CA002650999 A CA 002650999A CA 2650999 A CA2650999 A CA 2650999A CA 2650999 A1 CA2650999 A1 CA 2650999A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- compound
- cancer
- alkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68606205P | 2005-05-31 | 2005-05-31 | |
US60/686,062 | 2005-05-31 | ||
PCT/US2006/020986 WO2006130613A2 (en) | 2005-05-31 | 2006-05-30 | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2650999A1 true CA2650999A1 (en) | 2006-12-07 |
Family
ID=37482228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002650999A Abandoned CA2650999A1 (en) | 2005-05-31 | 2006-05-30 | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1896462A2 (ja) |
JP (1) | JP2008542382A (ja) |
CN (1) | CN101233129A (ja) |
AU (1) | AU2006252629A1 (ja) |
CA (1) | CA2650999A1 (ja) |
WO (1) | WO2006130613A2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
ES2541054T3 (es) * | 2010-10-20 | 2015-07-15 | Université De Bordeaux | Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales |
AU2016291676B2 (en) | 2015-07-16 | 2020-04-30 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001014350A1 (fr) * | 1999-08-23 | 2001-03-01 | Kyorin Pharmaceutical Co., Ltd. | Derives de benzylthiazolidine-2,4-dione substitues |
-
2006
- 2006-05-30 CN CNA2006800281850A patent/CN101233129A/zh active Pending
- 2006-05-30 AU AU2006252629A patent/AU2006252629A1/en not_active Abandoned
- 2006-05-30 EP EP06771644A patent/EP1896462A2/en not_active Withdrawn
- 2006-05-30 JP JP2008514781A patent/JP2008542382A/ja not_active Withdrawn
- 2006-05-30 CA CA002650999A patent/CA2650999A1/en not_active Abandoned
- 2006-05-30 WO PCT/US2006/020986 patent/WO2006130613A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2008542382A (ja) | 2008-11-27 |
CN101233129A (zh) | 2008-07-30 |
WO2006130613A3 (en) | 2007-02-08 |
WO2006130613A2 (en) | 2006-12-07 |
AU2006252629A1 (en) | 2006-12-07 |
EP1896462A2 (en) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2650999A1 (en) | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
JP5261575B2 (ja) | 化学化合物 | |
WO2013016720A2 (en) | Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
KR101433629B1 (ko) | 아연 결합 부분을 함유한 티로신 키나아제 억제제 | |
EP1605946B1 (en) | Thiazoles useful as inhibitors of protein kinases | |
AU2005230847B2 (en) | Anaplastic lymphoma kinase modulators and methods of use | |
US20040097566A1 (en) | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | |
AU2013283318B2 (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | |
TW202003505A (zh) | 甲基修飾酵素之調節劑、其組成物及用途 | |
AU2013230425B2 (en) | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists | |
SK4772002A3 (en) | Tyrosine kinase inhibitors, pharmaceutical composition containing the same and their use | |
JP5463592B2 (ja) | アデノシンa1レセプターアンタゴニストとしての新規化合物 | |
BR112012000370B1 (pt) | Compostos úteis como medicamentos | |
JP3555620B2 (ja) | N−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
RU2391342C2 (ru) | Новые азаиндолтиазолиноны в качестве противораковых агентов | |
US7897602B2 (en) | Indolinone compounds as kinase inhibitors | |
JP2008504324A (ja) | チアゾリノン非置換型キノリン | |
JP2005530705A (ja) | 糖尿病および他の疾患を治療するための複素環アミド誘導体 | |
CN101039939B (zh) | 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类 | |
JP2019523237A (ja) | 乳酸脱水素酵素の阻害剤としての1h−ピラゾール−1−イル−チアゾールおよびそれらの使用方法 | |
JP2008534646A (ja) | Cdk阻害剤としての置換1,5−ナフチリジンアゾリジノン | |
WO2006106721A1 (ja) | チロシンキナーゼ阻害作用を有するピリミジン誘導体 | |
US20050014767A1 (en) | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | |
RU2758259C2 (ru) | Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений | |
RU2395509C2 (ru) | Тиазолинон-2-замещенные хинолины |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |